内分泌科指南

订阅

MedSci主页 / 所有栏目 / 内分泌科指南

2019 日本建议：正确使用SGLT-2抑制剂

2019-11-15 日本糖尿病学会 J Diabetes Investig. 2019 Nov 15.

SGLT-2抑制剂

日本糖尿病学会于2019年8月6日发布了《关于正确使用SGLT2i专家建议》的日文版本，英文版本于2019年11月15日发布。主要内容包括： 1.关于SGLT-2i使用的一般建议。 2.与SGLT-2i相关的不良反应及对策，如： ➤严重低血糖（应如何减少胰岛素、磺脲类药物剂量） ➤酮症酸中毒 ➤脱水/脑梗死以及其他与脱水相关的并发症 ➤皮肤不良反应 ➤泌尿生殖系统感染

中文标题：

2019 日本建议：正确使用SGLT-2抑制剂

英文标题：

Recommendations on the Proper Use of SGLT2 Inhibitors.

发布机构：

日本糖尿病学会

发布日期：

2019-11-15

简要介绍：

日本糖尿病学会于2019年8月6日发布了《关于正确使用SGLT2i专家建议》的日文版本，英文版本于2019年11月15日发布。主要内容包括： 1.关于SGLT-2i使用的一般建议。 2.与SGLT-2i相关的不良反应及对策，如：

➤严重低血糖（应如何减少胰岛素、磺脲类药物剂量）

➤酮症酸中毒

➤脱水/脑梗死以及其他与脱水相关的并发症

➤皮肤不良反应

➤泌尿生殖系统感染

 

拓展指南：与糖尿病相关指南：

相关资料下载：
[AttachmentFileName(sort=100, fileName=2019 日本建议：正确使用SGLT-2抑制剂)] GetToolGuiderByIdResponse(projectId=1, id=d83631c00183e64f, title=2019 日本建议：正确使用SGLT-2抑制剂, enTitle=Recommendations on the Proper Use of SGLT2 Inhibitors., guiderFrom=J Diabetes Investig. 2019 Nov 15., authorId=null, author=, summary=日本糖尿病学会于2019年8月6日发布了《关于正确使用SGLT2i专家建议》的日文版本，英文版本于2019年11月15日发布。主要内容包括： 1.关于SGLT-2i使用的一般建议。 2.与SGLT-2i相关的不良反应及对策，如： ➤严重低血糖（应如何减少胰岛素、磺脲类药物剂量） ➤酮症酸中毒 ➤脱水/脑梗死以及其他与脱水相关的并发症 ➤皮肤不良反应 ➤泌尿生殖系统感染 , cover=, journalId=null, articlesId=null, associationId=1855, associationName=日本糖尿病学会, associationIntro=, copyright=0, guiderPublishedTime=Fri Nov 15 00:00:00 CST 2019, originalUrl=, linkOutUrl=, content=<P>日本糖尿病学会于2019年8月6日发布了《关于正确使用SGLT2i专家建议》的日文版本，英文版本于2019年11月15日发布。主要内容包括： 1.关于SGLT-2i使用的一般建议。 2.与SGLT-2i相关的不良反应及对策，如： <P>➤严重低血糖（应如何减少胰岛素、磺脲类药物剂量） <P>➤酮症酸中毒 <P>➤脱水/脑梗死以及其他与脱水相关的并发症 <P>➤皮肤不良反应 <P>➤泌尿生殖系统感染</P> <P> </P>拓展指南：<STRONG>与<FONT color=red>糖尿病</FONT>相关指南：</STRONG><BR> <UL> <LI><A title="2019 WMS临床实践指南：糖尿病的管理" target=_blank href="https://www.medsci.cn/guideline/show_article.do?id=663841c00183a81d">2019 WMS临床实践指南：糖尿病的管理</A> <LI><A title=《2019年欧洲心脏病学会和欧洲糖尿病研究学会糖尿病管理指南》解读 target=_blank href="https://www.medsci.cn/guideline/show_article.do?id=ae0501c00183a41b">《2019年欧洲心脏病学会和欧洲糖尿病研究学会糖尿病管理指南》解读</A> <LI><A title="2019 临床建议：糖尿病护理中动态血糖曲线的应用" target=_blank href="https://www.medsci.cn/guideline/show_article.do?id=32ff91c001828880">2019 临床建议：糖尿病护理中动态血糖曲线的应用</A> <LI><A title=治疗糖尿病药物及生物制品临床试验指导原则 target=_blank href="https://www.medsci.cn/guideline/show_article.do?id=193281c001818193">治疗糖尿病药物及生物制品临床试验指导原则</A> <LI><A title=治疗2型糖尿病新药的心血管风险评价指导原则 target=_blank href="https://www.medsci.cn/guideline/show_article.do?id=83c981c0018180c2">治疗2型糖尿病新药的心血管风险评价指导原则</A> 更多信息请点击：<A target=_blank href="https://www.medsci.cn/guideline/list.do?q=%E7%B3%96%E5%B0%BF%E7%97%85">有关糖尿病更多指南</A></LI></UL>, tagList=[TagDto(tagId=29077, tagName=SGLT-2抑制剂)], categoryList=[CategoryDto(categoryId=6, categoryName=内分泌科, tenant=100), CategoryDto(categoryId=8, categoryName=糖尿病, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=其他, guiderLanguage=0, guiderRegion=0, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=6021, appHits=446, showAppHits=3, pcHits=3348, showPcHits=3260, likes=88, shares=4, comments=5, approvalStatus=1, publishedTime=Fri Dec 13 00:08:11 CST 2019, publishedTimeString=2019-11-15, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Fri Dec 13 00:08:11 CST 2019, updatedBy=null, updatedName=null, updatedTime=Fri Jan 05 00:41:32 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2019 日本建议：正确使用SGLT-2抑制剂)])
2019 日本建议：正确使用SGLT-2抑制剂
下载请点击：
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1054473, encodeId=12bd10544e33a, content=下载学习哈 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/6DF3543CA4B977270D8CE734D49C26BA/100, createdBy=690e2536078, createdName=妖妖0, createdTime=Fri Sep 24 15:44:22 CST 2021, time=2021-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953228, encodeId=9ab69532282d, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cb355252510, createdName=147e4706m08暂无昵称, createdTime=Fri Apr 02 08:09:41 CST 2021, time=2021-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882217, encodeId=5bb188221ee8, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/05/04/7d4e27c5834b1a3e4b408bbcc7a5d2c5.jpg, createdBy=e51d5325936, createdName=逆行星, createdTime=Wed Sep 02 16:32:23 CST 2020, time=2020-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809852, encodeId=1c86809852ed, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d095409783, createdName=ms5000002046462755, createdTime=Mon Aug 17 21:05:55 CST 2020, time=2020-08-17, status=1, ipAttribution=)]
    2021-09-24 妖妖0

    下载学习哈

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1054473, encodeId=12bd10544e33a, content=下载学习哈 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/6DF3543CA4B977270D8CE734D49C26BA/100, createdBy=690e2536078, createdName=妖妖0, createdTime=Fri Sep 24 15:44:22 CST 2021, time=2021-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953228, encodeId=9ab69532282d, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cb355252510, createdName=147e4706m08暂无昵称, createdTime=Fri Apr 02 08:09:41 CST 2021, time=2021-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882217, encodeId=5bb188221ee8, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/05/04/7d4e27c5834b1a3e4b408bbcc7a5d2c5.jpg, createdBy=e51d5325936, createdName=逆行星, createdTime=Wed Sep 02 16:32:23 CST 2020, time=2020-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809852, encodeId=1c86809852ed, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d095409783, createdName=ms5000002046462755, createdTime=Mon Aug 17 21:05:55 CST 2020, time=2020-08-17, status=1, ipAttribution=)]
    2021-04-02 147e4706m08暂无昵称

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1054473, encodeId=12bd10544e33a, content=下载学习哈 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/6DF3543CA4B977270D8CE734D49C26BA/100, createdBy=690e2536078, createdName=妖妖0, createdTime=Fri Sep 24 15:44:22 CST 2021, time=2021-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953228, encodeId=9ab69532282d, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cb355252510, createdName=147e4706m08暂无昵称, createdTime=Fri Apr 02 08:09:41 CST 2021, time=2021-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882217, encodeId=5bb188221ee8, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/05/04/7d4e27c5834b1a3e4b408bbcc7a5d2c5.jpg, createdBy=e51d5325936, createdName=逆行星, createdTime=Wed Sep 02 16:32:23 CST 2020, time=2020-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809852, encodeId=1c86809852ed, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d095409783, createdName=ms5000002046462755, createdTime=Mon Aug 17 21:05:55 CST 2020, time=2020-08-17, status=1, ipAttribution=)]
    2020-09-02 逆行星

    谢谢

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1054473, encodeId=12bd10544e33a, content=下载学习哈 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/6DF3543CA4B977270D8CE734D49C26BA/100, createdBy=690e2536078, createdName=妖妖0, createdTime=Fri Sep 24 15:44:22 CST 2021, time=2021-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953228, encodeId=9ab69532282d, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cb355252510, createdName=147e4706m08暂无昵称, createdTime=Fri Apr 02 08:09:41 CST 2021, time=2021-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=882217, encodeId=5bb188221ee8, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/05/04/7d4e27c5834b1a3e4b408bbcc7a5d2c5.jpg, createdBy=e51d5325936, createdName=逆行星, createdTime=Wed Sep 02 16:32:23 CST 2020, time=2020-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=809852, encodeId=1c86809852ed, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d095409783, createdName=ms5000002046462755, createdTime=Mon Aug 17 21:05:55 CST 2020, time=2020-08-17, status=1, ipAttribution=)]
    2020-08-17 ms5000002046462755

    好

    0